These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 33383877)

  • 1. Pan-Genotype Pre-Exposure Prophylaxis (PrEP) Allows Transplantation of HCV-Positive Donor Kidneys to Negative Transplant Recipients.
    Duerr M; Liefeldt L; Friedersdorff F; Choi M; Öllinger R; Hofmann J; Budde K; Schrezenmeier E; Halleck F
    J Clin Med; 2020 Dec; 10(1):. PubMed ID: 33383877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expanding the Deceased Donor Pool in Manitoba Using Hepatitis C-Viremic Donors: Program Report.
    Cuvelier S; Van Caeseele P; Kadatz M; Peterson K; Sun S; Dodd N; Werestiuk K; Koulack J; Nickerson P; Ho J
    Can J Kidney Health Dis; 2021; 8():20543581211033496. PubMed ID: 34367648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of viral transmission during lung transplantation with hepatitis C-viraemic donors: an open-label, single-centre, pilot trial.
    Cypel M; Feld JJ; Galasso M; Pinto Ribeiro RV; Marks N; Kuczynski M; Kumar D; Bahinskaya I; Bagnato VS; Kurachi C; Slutsky AS; Yeung JC; Donahoe L; de Perrot M; Yasufuku K; Pierre A; Binnie M; Chaparro C; Martinu T; Chen M; Tikkanen J; Chow CW; Sidhu A; Waddell TK; Keshavjee S; Singer LG; Humar A
    Lancet Respir Med; 2020 Feb; 8(2):192-201. PubMed ID: 31606437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful early sofosbuvir-based antiviral treatment after transplantation of kidneys from HCV-viremic donors into HCV-negative recipients.
    Friebus-Kardash J; Gäckler A; Kribben A; Witzke O; Wedemeyer H; Treckmann J; Herzer K; Eisenberger U
    Transpl Infect Dis; 2019 Oct; 21(5):e13146. PubMed ID: 31306562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome of Kidney Transplants from Viremic and Non-Viremic Hepatitis C Virus Positive Donors into Negative Recipients: Results of the Spanish Registry.
    Franco A; Moreso F; Solà-Porta E; Beneyto I; Esforzado N; Gonzalez-Roncero F; Sancho A; Melilli E; Ruiz JC; Galeano C;
    J Clin Med; 2023 Feb; 12(5):. PubMed ID: 36902560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a single-center retrospective study.
    Bhamidimarri KR; Ladino M; Pedraza F; Guerra G; Mattiazzi A; Chen L; Ciancio G; Kupin W; Martin P; Burke G; Roth D
    Transpl Int; 2017 Sep; 30(9):865-873. PubMed ID: 28332729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increasing Utilization and Excellent Initial Outcomes Following Liver Transplant of Hepatitis C Virus (HCV)-Viremic Donors Into HCV-Negative Recipients: Outcomes Following Liver Transplant of HCV-Viremic Donors.
    Cotter TG; Paul S; Sandıkçı B; Couri T; Bodzin AS; Little EC; Sundaram V; Charlton M
    Hepatology; 2019 Jun; 69(6):2381-2395. PubMed ID: 30706517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of Using Kidneys From HCV-Viremic Donors for Transplantation Into HCV-Uninfected Recipients.
    Eckman MH; Woodle ES; Thakar CV; Alloway RR; Sherman KE
    Am J Kidney Dis; 2020 Jun; 75(6):857-867. PubMed ID: 32081494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of heart transplantation from hepatitis C virus-positive donors.
    Aslam S; Yumul I; Mariski M; Pretorius V; Adler E
    J Heart Lung Transplant; 2019 Dec; 38(12):1259-1267. PubMed ID: 31521479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients.
    Woolley AE; Singh SK; Goldberg HJ; Mallidi HR; Givertz MM; Mehra MR; Coppolino A; Kusztos AE; Johnson ME; Chen K; Haddad EA; Fanikos J; Harrington DP; Camp PC; Baden LR;
    N Engl J Med; 2019 Apr; 380(17):1606-1617. PubMed ID: 30946553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transplantation of kidneys from HCV-positive donors: a safe strategy?
    Fabrizi F; Bunnapradist S; Lunghi G; Martin P
    J Nephrol; 2003; 16(5):617-25. PubMed ID: 14733406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes in HIV+/HCV+ coinfected kidney transplant recipients in the pre- and post-direct-acting antiviral therapy eras: 10-Year single center experience.
    Camargo JF; Anjan S; Chin-Beckford N; Morris MI; Abbo LM; Simkins J; Ciancio G; Chen LJ; Burke GW; Figueiro J; Guerra G; Kupin WL; Mattiazzi A; Ortigosa-Goggins M; Ram Bhamidimarri K; Roth D
    Clin Transplant; 2019 May; 33(5):e13532. PubMed ID: 30866102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early Results of Pilot Study Using Hepatitis C Virus (HCV) Positive Kidneys to Transplant HCV Infected Patients with End-Stage Renal Disease Allowing for Successful Interferon-Free Direct Acting Antiviral Therapy after Transplantation.
    Gallegos-Orozco JF; Kim R; Thiesset HF; Hatch J; Lynch K; Chaly T; Shihab F; Ahmed F; Hall I; Campsen J
    Cureus; 2016 Nov; 8(11):e890. PubMed ID: 28018760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-emptive pangenotypic direct acting antiviral therapy in donor HCV-positive to recipient HCV-negative heart transplantation: an open-label study.
    Bethea ED; Gaj K; Gustafson JL; Axtell A; Lebeis T; Schoenike M; Turvey K; Coglianese E; Thomas S; Newton-Cheh C; Ibrahim N; Carlson W; Ho JE; Shah R; Nayor M; Gift T; Shao S; Dugal A; Markmann J; Elias N; Yeh H; Andersson K; Pratt D; Bhan I; Safa K; Fishman J; Kotton C; Myoung P; Villavicencio MA; D'Alessandro D; Chung RT; Lewis GD
    Lancet Gastroenterol Hepatol; 2019 Oct; 4(10):771-780. PubMed ID: 31353243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes After Direct-Acting Antiviral Therapy Based on Donor Hepatitis C Serostatus Among Hepatitis C Virus-Infected Kidney Transplant Recipients.
    Sedki M; Cortesi C; O'Brien C; Levy C; Martin P; Roth D; Bhamidimarri KR
    Exp Clin Transplant; 2020 Mar; ():. PubMed ID: 32133941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transplantation of HCV Viremic Livers into HCV Viremic Recipients Followed by Direct-acting Antiviral Therapy.
    Kapila N; Khalloufi KA; Flocco G; Menon KVN; Lindenmeyer C; Reino D; Vanatta JM; Ebaid S; Tzakis A; Zervos XB
    J Clin Transl Hepatol; 2019 Jun; 7(2):122-126. PubMed ID: 31293911
    [No Abstract]   [Full Text] [Related]  

  • 17. Shorter waiting times for hepatitis C virus seropositive recipients of cadaveric renal allografts from hepatitis C virus seropositive donors.
    Mandal AK; Kraus ES; Samaniego M; Rai R; Humphreys SL; Ratner LE; Maley WR; Burdick JF
    Clin Transplant; 2000 Aug; 14(4 Pt 2):391-6. PubMed ID: 10946777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C transmission from seropositive, nonviremic donors to non-hepatitis C liver transplant recipients.
    Bari K; Luckett K; Kaiser T; Diwan T; Cuffy M; Schoech MR; Safdar K; Blackard JT; Apewokin S; Paterno F; Sherman KE; Zucker SD; Anwar N; Shah SA
    Hepatology; 2018 May; 67(5):1673-1682. PubMed ID: 29205441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in Utilization and Discard of HCV Antibody-Positive Deceased Donor Kidneys in the Era of Direct-Acting Antiviral Therapy.
    Bowring MG; Kucirka LM; Massie AB; Ishaque T; Bae S; Shaffer AA; Garonzik Wang J; Sulkowski M; Desai N; Segev DL; Durand CM
    Transplantation; 2018 Dec; 102(12):2088-2095. PubMed ID: 29912046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in waiting list composition.
    Crespo G; Trota N; Londoño MC; Mauro E; Baliellas C; Castells L; Castellote J; Tort J; Forns X; Navasa M
    J Hepatol; 2018 Jul; 69(1):11-17. PubMed ID: 29481821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.